ESTRO Brachytherapy for Prostate Cancer 2018

Secondary malignancy after prostate radiation

• Liauw et al reported a 4.3% incidence in second cancers at 15 years after BT (n=125) or BT + EBXRT (n=223) • bladder 3.1% • colorectal 0.8% Absolute excess risk 35 per 10 000 treated patients